LQDA

Peers: UTHR MNKD INSM BCRX XERS SUPN GOSS CYTK TENX KROS

| Held by: IJR VTI IWM XSMO IJT SPSM IWO VXF VB SLYG

Index	RUT
Market Cap	3.54B
Enterprise Value	3.44B
Income	138.61M
Sales	450.91M
Book/sh	2.19
Cash/sh	3.17
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	216
IPO	Jul 26, 2018

P/E	29.03
Forward P/E	18.11
PEG	-
P/S	7.86
P/B	18.08
P/C	12.47
P/FCF	23.52
EV/EBITDA	20.22
EV/Sales	7.64
Quick Ratio	2.12
Current Ratio	2.31
Debt/Eq	0.94
LT Debt/Eq	0.66
Option/Short	Yes / Yes

EPS (ttm)	1.36
EPS next Y	2.19
EPS next Q	0.92
EPS this Y	361.41%
EPS next Y	4.55%
EPS next 5Y	-
EPS past 3/5Y	-5.98% 14.60%
Sales past 3/5Y	114.98% 192.49%
EPS Y/Y TTM	193.03%
Sales Y/Y TTM	2233.65%
EPS Q/Q	251.69%
Sales Q/Q	1842.73%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-0.36% 1.90%

Insider Own	13.45%
Insider Trans	-20.17%
Inst Own	79.98%
Inst Trans	15.28%
ROA	35.57%
ROE	131.82%
ROIC	42.89%
Gross Margin	92.30%
Oper. Margin	37.39%
Profit Margin	30.74%
SMA20	6.77%
SMA50	-29.96%
SMA200	-26.70%
Trades

Shs Outstand	89.10M
Shs Float	77.47M
Short Float	16.32%
Short Ratio	3.96
Short Interest	12.64M
52W High	93.61 -57.70%
52W Low	21.94 80.49%
Volatility	8.42% 16.01%
ATR (14)	4.32
RSI (14)	44.47
Beta	0.49
Rel Volume	0.82
Avg Volume	3.19M
Volume	2,016,367

Perf Week	13.86%
Perf Month	-41.32%
Perf Quarter	-54.07%
Perf Half Y	5.71%
Perf YTD	14.82%
Perf Year	77.26%
Perf 3Y	542.34%
Perf 5Y	1003.06%
Perf 10Y	-
Recom	1.78
Target Price	54.38
Prev Close	38.86
Price	39.60
Change %	1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-26	Upgrade	BTIG Research	Neutral → Buy	$70
Oct-02-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$30
Oct-01-26	Downgrade	Raymond James	Strong Buy → Outperform	$53
Oct-01-26	Downgrade	BTIG Research	Buy → Neutral
Jun-29-26	Downgrade	BofA Securities	Buy → Neutral	$79
Oct-20-25	Initiated	Wells Fargo	Overweight	$31
Aug-15-25	Resumed	Jefferies	Buy	$43
May-19-25	Downgrade	Oppenheimer	Perform → Underperform	$13
Dec-20-24	Initiated	Wells Fargo	Overweight	$20
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6

Show Previous Ratings

Oct-16-26 05:26AM	Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure (Stocktwits)
Oct-14-26 09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis) +26.59%
12:07PM	Liquidia shares surge 25% as settlement ends United Therapeutics litigation (Proactive)
10:24AM	?? Under the Radar: Liquidia Stock Soars After Settling Patent Fight (The Wall Street Journal)
10:15AM	LQDA Stock Rockets 40% Today BTIG Calls United Therapeutics Settlement Better Than Best-Case Scenario (Stocktwits)
08:57AM	Loading…
08:57AM	This Biotech Stock Surges 37% on Patent Settlement. 'Better Than the Best-Case Scenario.' (Barrons.com)
07:11AM	Premarket movers: Alibaba gains on new AI glasses; Liquidia rallies as legal eases (Investing.com)
05:13AM	Liquidia shares surge to 5-month high premarket on United Therapeutics settlement (Investing.com)
Oct-13-26 07:39PM	LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market (Stocktwits)
06:26PM	Liquidia stock surges 40% on $380.7M litigation settlement with UTHR (Investing.com)
05:44PM	Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH (GlobeNewswire)
Oct-02-26 06:40AM	Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb Liquidia And FICO Face Downgrades (Stocktwits)
Oct-01-26 02:07PM	LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path (Stocktwits) -7.50%
10:14AM	Liquidia Sinks Another 17% as BofA Cuts Target to $40 From $92 After Court Loss (TIKR)
09:38AM	Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls (The Fly)
01:03AM	Loading…
01:03AM	Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling. An Appeal Could Decide Whether Shares Rebound. (TIKR)
Sep-30-26 09:41PM	United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent (TIKR) -57.19%
03:46PM	LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims (Stocktwits)
02:23PM	Liquidia shares crater after court rules for United Therapeutics (Investing.com)
01:20PM	Liquidia Provides Update on Hatch-Waxman Litigation Tied to '327 Patent (GlobeNewswire)
Sep-03-26 07:30AM	FDA Grants Fast Track Designation to YUTREPIA for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis (GlobeNewswire)
Sep-02-26 08:30AM	Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress (GlobeNewswire)
Sep-01-26 08:30AM	Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference (GlobeNewswire)
Aug-12-26 07:03PM	Liquidia Corp (LQDA) (Q2 2026) Earnings Call Highlights: YUTREPIA Sales Surge 31% as Company ... (GuruFocus.com) -10.52% -8.49%
05:03PM	Liquidia Corporation Q2 2026 Earnings Call Summary (Moby)
09:06AM	Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat (Stocktwits)
07:24AM	Liquidia shares fall after second-quarter earnings miss despite revenue growth (InvestorsHub)
06:30AM	Liquidia Corporation Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
Jul-29-26 08:30AM	Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
12:01PM	Loading…
Jun-29-26 12:01PM	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com)
Jun-11-26 08:30AM	Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions (GlobeNewswire) +9.77%
Jun-08-26 08:30AM	Liquidia Corporation Announces Inclusion in the S&P SmallCap 600 Index (GlobeNewswire)
Jun-05-26 07:25PM	Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
May-27-26 08:30AM	Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 03:03AM	Liquidia Corp (LQDA) Q1 2026 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) +6.53%
May-11-26 04:56PM	Liquidia Corporation Q1 2026 Earnings Call Summary (Moby) +25.60%
10:10AM	Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat (InvestorsHub)
06:30AM	Liquidia Corporation Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 08:30AM	Liquidia Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.01%
May-04-26 08:30AM	Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026 (GlobeNewswire)
Apr-07-26 08:00AM	Liquidia Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-03-26 08:00PM	Does Liquidia Corporation (LQDA) Have the Potential to Rally 34.47% as Wall Street Analysts Expect? (Quartz)
Mar-10-26 10:00AM	Best Momentum Stocks to Buy for March 10th (Zacks) +8.25%
Mar-05-26 10:10PM	Liquidia Q4 Earnings Call Highlights (MarketBeat)
04:02PM	Liquidia Corp (LQDA) Q4 2025 Earnings Call Highlights: Record Sales Surge and Strategic Growth (GuruFocus.com)
08:30AM	Liquidia Corporation Q4 2025 Earnings Call Summary (Moby)
07:45AM	Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 12:15PM	Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Feb-16-26 11:07AM	Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling (Insider Monkey)
Feb-12-26 11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
Jan-27-26 08:30AM	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress (GlobeNewswire)
Jan-16-26 08:29AM	Laughing Water Capital's Updates on Liquidia Corp (LQDA) (Insider Monkey)
Jan-15-26 12:00PM	Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-09-26 07:09PM	Why Liquidia Stock Rocked the Market Today (Motley Fool) +12.91%
06:30AM	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update (GlobeNewswire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
Jan-07-26 07:00AM	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
Dec-11-25 09:22AM	Arquitos Capital Management's Updates on Liquidia Corporation (LQDA) (Insider Monkey)
Nov-24-25 09:55AM	Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
Nov-16-25 10:14PM	Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA's 75% Growth in U.S. Prostacyclin Revenue (Insider Monkey)
Nov-06-25 09:55AM	Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet (Zacks)
Nov-05-25 06:39AM	Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment (Insider Monkey) -5.34%
Nov-03-25 04:02PM	Liquidia Corp (LQDA) Q3 2025 Earnings Call Highlights: Strong YUTREPIA Sales Drive Positive ... (GuruFocus.com) +10.67%
08:00AM	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences (GlobeNewswire)
06:30AM	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 09:21AM	Liquidia Corp (LQDA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
Oct-28-25 10:00AM	Niagen Bioscience (NAGE) Reports Next Week: What to Expect (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 08:30AM	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade (Zacks)
Oct-16-25 04:33PM	BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating (Insider Monkey)
Oct-07-25 06:30AM	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 (GlobeNewswire) +5.10%
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
Sep-29-25 08:30AM	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting (GlobeNewswire)
Sep-24-25 04:06AM	Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo's Annual Healthcare Conference 2025 (Insider Monkey)
Sep-23-25 10:32AM	Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? (Insider Monkey)
Sep-16-25 02:15PM	Liquidia Corporation (LQDA): A Bull Case Theory (Insider Monkey)
Sep-11-25 08:30AM	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium (GlobeNewswire)
Sep-04-25 01:14PM	Jefferies Highlights Yutrepia's Market Edge in Supporting a Buy on Liquidia (LQDA) (Insider Monkey)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
Sep-01-25 01:04AM	BTIG Raises Price Target for Liquidia (LQDA), Keeps Buy Rating (Insider Monkey)
Aug-27-25 08:30AM	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-25 11:40PM	Court Victory and Fresh Funding Propel Growth at Liquidia Corporation (Insider Monkey) +6.82%
Aug-13-25 12:54PM	Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge (Insider Monkey)
03:08AM	Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position (GuruFocus.com)
Aug-12-25 04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily) +13.68%
03:00PM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
06:30AM	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:22AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result (GuruFocus.com)
Aug-05-25 08:30AM	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schundler Russell	General Counsel	Oct 12 '26	Sale	28.48	13,692	389,948	602,841	Oct 13 08:05 PM
Saggar Rajeev	Chief Medical Officer	Oct 12 '26	Sale	28.48	9,218	262,529	126,368	Oct 13 08:04 PM
Moomaw Scott	Chief Commercial Officer	Oct 12 '26	Sale	28.48	8,863	252,418	181,487	Oct 13 08:03 PM
Krepp Sarah	Chief Human Resource Officer	Oct 12 '26	Sale	28.48	5,245	149,378	115,241	Oct 13 08:02 PM
Khindri Sanjeev	Chief Development Officer	Oct 12 '26	Sale	28.48	1,101	31,356	64,846	Oct 13 08:01 PM
Kaseta Michael	CFO and COO	Oct 12 '26	Sale	28.48	18,938	539,354	340,148	Oct 13 08:00 PM
JEFFS ROGER	Chief Executive Officer	Oct 12 '26	Sale	28.48	32,744	932,549	1,125,848	Oct 13 07:59 PM
Boyle Dana	Chief Accounting Officer	Oct 12 '26	Sale	28.48	5,892	167,804	165,609	Oct 13 07:59 PM
Adair Jason	Chief Business Officer	Oct 12 '26	Sale	28.48	7,301	207,932	177,957	Oct 13 07:58 PM
Bloch Stephen M	Director	Oct 05 '26	Sale	27.13	235,477	6,387,596	0	Oct 07 04:30 PM
SINGH RAMAN	Director	Sep 11 '26	Option Exercise	9.26	9,024	83,597	53,661	Sep 15 04:30 PM
SINGH RAMAN	Director	Sep 14 '26	Option Exercise	9.31	8,468	78,799	53,105	Sep 15 04:30 PM
SINGH RAMAN	Director	Sep 11 '26	Sale	68.62	9,024	619,210	44,637	Sep 15 04:30 PM
SINGH RAMAN	Director	Sep 14 '26	Sale	66.16	8,468	560,243	44,637	Sep 15 04:30 PM
RAMANDEEP SINGH	Director	Sep 14 '26	Proposed Sale	66.16	8,468	560,243		Sep 14 04:11 PM
RAMANDEEP SINGH	Director	Sep 11 '26	Proposed Sale	68.62	9,024	619,210		Sep 11 05:17 PM
Adair Jason	Chief Business Officer	Aug 21 '26	Option Exercise	11.00	31,799	349,839	248,237	Aug 25 04:30 PM
Adair Jason	Chief Business Officer	Aug 21 '26	Sale	69.09	73,631	5,087,225	174,606	Aug 25 04:30 PM
JASON ADAIR	Officer	Aug 21 '26	Proposed Sale	71.05	73,631	5,231,483		Aug 21 04:37 PM
Rielly-Gauvin Katherine	Director	Aug 19 '26	Option Exercise	2.54	36,789	93,407	81,426	Aug 21 04:30 PM
Rielly-Gauvin Katherine	Director	Aug 20 '26	Option Exercise	2.54	18,393	46,700	63,030	Aug 21 04:30 PM
Rielly-Gauvin Katherine	Director	Aug 19 '26	Sale	74.99	36,789	2,758,958	44,637	Aug 21 04:30 PM
Rielly-Gauvin Katherine	Director	Aug 20 '26	Sale	72.23	18,393	1,328,477	44,637	Aug 21 04:30 PM
Saggar Rajeev	Chief Medical Officer	Aug 19 '26	Option Exercise	3.73	50,000	186,500	192,265	Aug 19 06:21 PM
Saggar Rajeev	Chief Medical Officer	Aug 19 '26	Sale	74.06	50,000	3,702,825	142,265	Aug 19 06:21 PM
Saggar Rajeev	Chief Medical Officer	Aug 17 '26	Sale	76.84	29,534	2,269,381	142,265	Aug 19 06:21 PM
Katherine T. Rielly-Gauvin	Director	Aug 19 '26	Proposed Sale	74.33	55,182	4,101,678		Aug 19 04:26 PM
RAJEEV SAGGAR	Officer	Aug 19 '26	Proposed Sale	74.06	50,000	3,702,825		Aug 19 04:04 PM
RAJEEV SAGGAR	Officer	Aug 17 '26	Proposed Sale	76.84	29,534	2,269,381		Aug 17 05:01 PM
Boyle Dana	Chief Accounting Officer	Jul 27 '26	Sale	87.53	1,600	140,048	167,919	Jul 29 04:30 PM
Adair Jason	Chief Business Officer	Jul 27 '26	Sale	87.53	688	60,221	216,438	Jul 29 04:30 PM
Bloch Stephen M	Director	Jul 23 '26	Sale	89.48	100,000	8,948,444	501,477	Jul 24 04:30 PM
Bloch Stephen M	Director	Jul 22 '26	Sale	88.38	100,000	8,837,965	601,477	Jul 24 04:30 PM
Bloch Stephen M	Director	Jul 21 '26	Sale	79.99	75,000	5,999,182	701,477	Jul 22 07:31 PM
Bloch Stephen M	Director	Jul 20 '26	Sale	79.55	3,596	286,068	776,477	Jul 22 07:31 PM
Krepp Sarah	Chief Human Resource Officer	Jul 13 '26	Sale	71.51	7,864	562,361	117,178	Jul 14 08:11 PM
Khindri Sanjeev	Chief Development Officer	Jul 13 '26	Sale	71.51	1,185	84,740	65,947	Jul 14 08:09 PM
Kaseta Michael	CFO and COO	Jul 13 '26	Sale	71.51	20,430	1,460,965	345,805	Jul 14 08:08 PM
JEFFS ROGER	Chief Executive Officer	Jul 13 '26	Sale	71.51	35,249	2,520,683	1,130,426	Jul 14 08:07 PM
Adair Jason	Chief Business Officer	Jul 13 '26	Sale	71.51	7,863	562,289	217,126	Jul 14 08:05 PM
Schundler Russell	General Counsel	Jul 13 '26	Sale	71.51	14,738	1,053,926	605,962	Jul 14 08:04 PM
Saggar Rajeev	Chief Medical Officer	Jul 13 '26	Sale	71.51	9,926	709,816	171,799	Jul 14 08:02 PM
Moomaw Scott	Chief Commercial Officer	Jul 13 '26	Sale	71.51	9,539	682,142	182,485	Jul 14 08:01 PM
Boyle Dana	Chief Accounting Officer	Jul 13 '26	Sale	71.51	9,002	643,740	169,519	Jul 14 07:59 PM
Bloch Stephen M	Director	Jul 07 '26	Sale	80.94	50,000	4,046,795	780,073	Jul 08 04:30 PM
Bloch Stephen M	Director	Jul 06 '26	Sale	80.17	25,000	2,004,375	830,073	Jul 08 04:30 PM
Bloch Stephen M	Director	Jul 01 '26	Sale	79.47	25,000	1,986,695	855,073	Jul 06 05:44 PM
Bloch Stephen M	Director	Jun 22 '26	Sale	75.74	100,000	7,573,704	880,073	Jun 24 04:30 PM
Bloch Stephen M	Director	Jun 12 '26	Sale	71.46	111,049	7,936,094	1,065,135	Jun 16 04:30 PM
Bloch Stephen M	Director	Jun 15 '26	Sale	71.44	85,062	6,076,486	980,073	Jun 16 04:30 PM
Krepp Sarah	Chief Human Resource Officer	Jun 11 '26	Sale	70.28	24,880	1,748,527	121,863	Jun 15 04:30 PM
Bloch Stephen M	Director	Jun 11 '26	Sale	70.43	242,269	17,062,444	1,176,184	Jun 12 04:30 PM
Bloch Stephen M	Director	Jun 10 '26	Sale	65.58	145,954	9,572,345	1,418,453	Jun 12 04:30 PM
SARAH KREPP	Officer	Jun 11 '26	Proposed Sale	65.25	24,880	1,623,420		Jun 11 04:26 PM
Canaan VIII LP	Director	Jun 10 '26	Proposed Sale	65.00	200,000	13,000,000		Jun 10 04:52 PM
Khindri Sanjeev	Chief Development Officer	Jun 08 '26	Sale	65.46	4,134	270,612	67,132	Jun 10 04:31 PM
Bloch Stephen M	Director	Jun 08 '26	Sale	64.76	148,301	9,603,989	1,636,941	Jun 10 04:30 PM
Bloch Stephen M	Director	Jun 09 '26	Sale	64.38	72,534	4,669,693	1,564,407	Jun 10 04:30 PM
Manning Paul B	Director	Jun 04 '26	Sale	63.91	200,000	12,782,059	716,311	Jun 08 04:41 PM
Bloch Stephen M	Director	Jun 04 '26	Sale	64.97	82,736	5,375,398	1,787,306	Jun 08 04:30 PM
Bloch Stephen M	Director	Jun 05 '26	Sale	64.14	2,064	132,384	1,785,242	Jun 08 04:30 PM
Canaan VIII LP	Director	Jun 08 '26	Proposed Sale	64.00	200,000	12,800,000		Jun 08 04:11 PM
Paul B Manning	Director	Jun 04 '26	Proposed Sale	55.69	200,000	11,138,000		Jun 04 06:38 PM
Canaan VIII LP	Director	Jun 04 '26	Proposed Sale	65.00	200,000	13,000,000		Jun 04 05:24 PM
Krepp Sarah	Chief Human Resource Officer	Jun 01 '26	Sale	60.87	276	16,800	146,743	Jun 03 04:31 PM
KIRSCH ARTHUR S	Director	Jun 01 '26	Sale	60.22	15,000	903,300	15,000	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 03 '26	Sale	54.80	10,000	548,000	0	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 02 '26	Sale	56.00	5,000	280,000	10,000	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 01 '26	Proposed Sale	61.37	30,000	1,841,100		Jun 01 09:56 AM
JEFFS ROGER	Chief Executive Officer	May 27 '26	Sale	62.18	6,428	399,712	1,041,667	May 28 04:30 PM
SINGH RAMAN	Director	May 21 '26	Option Exercise	9.44	29,494	278,352	68,249	May 26 06:17 PM
SINGH RAMAN	Director	May 21 '26	Sale	60.13	29,494	1,773,436	38,755	May 26 06:17 PM
JEFFS ROGER	Chief Executive Officer	May 22 '26	Sale	61.52	25,000	1,538,055	1,073,095	May 26 06:16 PM
JEFFS ROGER	Chief Executive Officer	May 21 '26	Sale	61.13	25,000	1,528,160	1,098,095	May 26 06:16 PM
JEFFS ROGER	Chief Executive Officer	May 26 '26	Sale	60.38	25,000	1,509,460	1,048,095	May 26 06:16 PM
RAMANDEEP SINGH	Director	May 21 '26	Proposed Sale	60.13	29,494	1,773,437		May 21 05:12 PM
Caligan Partners LP	Director	May 19 '26	Buy	59.98	5,300	317,894	8,138,951	May 20 08:51 PM
Caligan Partners LP	Director	May 19 '26	Sale	59.98	5,300	317,894	8,133,651	May 20 08:51 PM
JEFFS ROGER	Chief Executive Officer	May 20 '26	Sale	61.30	25,000	1,532,548	1,123,095	May 20 06:55 PM
JEFFS ROGER	Chief Executive Officer	May 19 '26	Sale	58.65	25,000	1,466,142	1,148,095	May 20 06:55 PM
JEFFS ROGER	Chief Executive Officer	May 18 '26	Sale	56.77	25,000	1,419,320	1,173,095	May 20 06:55 PM
SERENDIPITY BIOPHARMA LLC	Director	May 20 '26	Proposed Sale	59.98	106,428	6,383,551		May 20 04:37 PM
JEFFS ROGER	Chief Executive Officer	May 14 '26	Sale	58.62	25,000	1,465,565	1,223,095	May 15 06:59 PM
JEFFS ROGER	Chief Executive Officer	May 15 '26	Sale	57.04	25,000	1,426,072	1,198,095	May 15 06:59 PM
JEFFS ROGER	Chief Executive Officer	May 13 '26	Sale	56.29	25,000	1,407,128	1,248,095	May 15 06:59 PM
SERENDIPITY BIOPHARMA LLC	Director	May 14 '26	Proposed Sale	57.59	100,000	5,759,000		May 14 04:26 PM
Bloch Stephen M	Director	May 11 '26	Sale	50.23	318,893	16,016,775	1,870,042	May 13 04:30 PM
JEFFS ROGER	Chief Executive Officer	May 12 '26	Sale	54.04	25,000	1,350,990	1,273,095	May 12 06:52 PM
JEFFS ROGER	Chief Executive Officer	May 08 '26	Sale	42.14	25,000	1,053,565	1,323,095	May 12 06:52 PM
JEFFS ROGER	Chief Executive Officer	May 11 '26	Sale	41.50	25,000	1,037,402	1,298,095	May 12 06:52 PM
Canaan VIII LP	Director	May 11 '26	Proposed Sale	49.86	318,893	15,900,000		May 11 05:52 PM
SERENDIPITY BIOPHARMA LLC	Director	May 08 '26	Proposed Sale	42.28	100,000	4,228,000		May 08 04:19 PM
JEFFS ROGER	Chief Executive Officer	May 07 '26	Sale	42.09	25,000	1,052,135	1,348,095	May 07 06:19 PM
JEFFS ROGER	Chief Executive Officer	May 06 '26	Sale	40.78	25,000	1,019,572	1,373,095	May 07 06:19 PM
JEFFS ROGER	Chief Executive Officer	May 05 '26	Sale	40.10	25,000	1,002,593	1,398,095	May 07 06:19 PM
SERENDIPITY BIOPHARMA LLC	Director	May 07 '26	Proposed Sale	42.14	25,000	1,053,500		May 07 04:18 PM
Boyle Dana	Chief Accounting Officer	Apr 27 '26	Sale	37.78	1,576	59,541	175,342	Apr 29 04:31 PM
Adair Jason	Chief Business Officer	Apr 27 '26	Sale	41.65	688	28,655	214,738	Apr 29 04:30 PM
JEFFS ROGER	Chief Executive Officer	Apr 17 '26	Sale	40.60	18,839	764,956	1,423,095	Apr 21 04:30 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 17 '26	Proposed Sale	41.40	68,839	2,849,935		Apr 17 04:39 PM

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

CEO & DirectorDr. Roger A. Jeffs Ph.D.

COO & CFOMr. Michael Kaseta

General Counsel & Corporate SecretaryMr. Russell Schundler

Chief Commercial OfficerMr. Scott Moomaw

Chief Medical OfficerDr. Rajeev Saggar M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Liquidia Corp

Upgrade your Finviz experience